Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Progress in Organ Bioprinting for Regenerative Medicine

Wang X., Zhang D., Singh YP., Yeo M., Deng G., Lai J.

Laboratory Study on Systemic / IV, published in Engineering (Beijing) (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Engineering (Beijing) (2024)
Reported sample size
—
Source database
Europe PMC
PMID
41567882
PMCID
PMC12818943
DOI
10.1016/j.eng.2024.04.023
Citations
4

Abstract (original English)

Organ damage or failure arising from injury, disease, and aging poses challenges due to the body's limited regenerative capabilities. Organ transplantation presents the issues of donor shortages and immune rejection risks, necessitating innovative solutions. The three-dimensional (3D) bioprinting of organs on demand offers promise in tissue engineering and regenerative medicine. In this review, we explore the state-of-the-art bioprinting technologies, with a focus on bioink and cell type selections. We follow with discussions on advances in the bioprinting of solid organs, such as the heart, liver, kidney, and pancreas, highlighting the importance of vascularization and cell integration. Finally, we provide insights into key challenges and future directions in the context of the clinical translation of bioprinted organs and their large-scale production.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research